Intarcia Therapeutics appoints Head of Global Medical Affairs, Safety and Operations

John Yee takes the newly created position at the US biopharmaceutical firm

US biopharmaceutical firm Intarcia Therapeutics has appointed John Yee as Vice President, Head of Global Medical Affairs, Safety and Operations, a newly created position.

Yee has two decades of experience at leading pharmaceutical, biotechnology, and healthcare companies, and at an academic medical centre.

Most recently Yee was VP, Head of Medical Affairs, US Diabetes, and VP, US Head Medical Officer at AstraZeneca, where he led medical affairs across all therapeutic areas, and the medical launch of multiple cardiovascular and metabolic products.

In his career prior to AstraZeneca, Yee served in progressive leadership roles at Genzyme, including Global Medical Director; VP, US Medical Affairs; and VP, Global Medical Affairs for the company's rare genetic disease business and VP, Global Head, Evidence-Based Medicine across all therapeutic areas.

In his new role, Yee will be a member of the leadership team and an executive officer of the company, reporting to Kurt Graves, Chairman, President and CEO.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Manufacturing

Servier opens new €86m biologics production facility in Loiret, France

The company's Bio-S facility will be responsible for the production of biological medicines stemming from its R&D pipeline for preclinical and clinical studies
Manufacturing

Leybold launches Duradry vacuum pump for harsh processes

Advanced technology designed for reliability and efficiency
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Subscribe now